Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PYPD
PYPD logo

PYPD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy PolyPid Ltd (PYPD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.620
1 Day change
1.09%
52 Week Range
5.210
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

PolyPid Ltd (PYPD) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading in pre-market near $4.60 with only a slight gain, and the technicals are mixed-to-weak rather than confirming an uptrend. There is no supportive news, no strong proprietary buy signal, and no recent analyst or insider activity to suggest a fresh catalyst. For an impatient investor wanting an immediate decision, the best call is to hold off and not buy now.

Technical Analysis

The current technical picture is neutral to mildly bearish. MACD histogram is -0.0417 and still below zero, indicating momentum remains weak even though it is contracting. RSI_6 at 43.2 sits in the neutral zone, showing neither oversold nor strong bullish momentum. Moving averages are converging, which usually signals indecision rather than a clear trend. Price is sitting below the pivot at 4.769, with nearby resistance at 5.079 and 5.27, while support is at 4.46 and 4.269. Pre-market price at 4.595 is only slightly above support, so the current setup does not show a compelling breakout or strong trend reversal.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is mildly bullish based on the low open interest put-call ratio of 0.36, which suggests more call interest than put interest. However, the actual option volume is extremely thin at just 6 calls and 0 puts, so the signal is not very reliable. Implied volatility is very high at 167.86, while IV rank and percentile are low, showing the market still expects large movement but recent IV is not elevated versus its own history. Overall, options data leans cautiously positive, but liquidity is weak and does not create a strong buy case.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
7

Positive Catalysts

  • ["Mildly bullish options positioning with open interest put-call ratio of 0.36", "Pre-market trading is slightly positive at 4.595, up 0.55%", "Similar candlestick pattern analysis suggests a potential short-term upside bias", "No significant negative news in the past week"]

Neutral/Negative Catalysts

  • ["No recent news catalysts in the last week", "MACD remains below zero, showing weak momentum", "RSI is neutral, not signaling strong buying pressure", "Moving averages are only converging, not trending upward decisively", "No AI Stock Picker signal today", "No SwingMax signal recently", "No notable insider buying or selling activity", "No meaningful hedge fund trend over the last quarter", "No recent congress trading data", "Financial snapshot data is unavailable, limiting confirmation of business performance"]

Financial Performance

No usable latest-quarter financial snapshot was provided because of a data error, so I cannot verify revenue or earnings growth for the most recent quarter season. As a result, there is no fundamental evidence here to support an immediate long-term buy.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no visible Wall Street upgrade/downgrade momentum or target-price revision trend to support a bullish thesis. Wall Street pros appear neutral by default due to the absence of fresh analyst conviction.

Wall Street analysts forecast PYPD stock price to rise
3 Analyst Rating
Wall Street analysts forecast PYPD stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.570
sliders
Low
9
Averages
11
High
13
Current: 4.570
sliders
Low
9
Averages
11
High
13
Roth Capital
Buy
downgrade
$10 -> $9
AI Analysis
2025-11-13
Reason
Roth Capital
Price Target
$10 -> $9
AI Analysis
2025-11-13
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on PolyPid to $9 from $10 and keeps a Buy rating on the shares following the Q3 report. The firm expects a positive pre-new drug application meeting and a potential filing submission in the first half of 2026 for PolyPid. Given that D-PLEX100 "enjoys multiple designations" from the FDA, it should get a six-month review, the analyst tells investors in a research note.
Roth Capital
Buy
maintain
$9 -> $10
2025-08-14
Reason
Roth Capital
Price Target
$9 -> $10
2025-08-14
maintain
Buy
Reason
Roth Capital raised the firm's price target on PolyPid to $10 from $9 and keeps a Buy rating on the shares after meeting with its management following the company's Q2 results. The firm expects a fairly uneventful pre-NDA meeting given solid D-PLEX100 clinical data, which Roth believes is poised to transform the treatment paradigm in SSI associated with colorectal cancer surgery, providing benefits to patients and healthcare systems, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PYPD
Unlock Now

People Also Watch